A synthetic Tn-BSA conjugate vaccine bearing chitotriose as built-in adjuvant

Chitotriose (CTS), the hydrolysate of chitosan, is readily soluble in water because of the shorter chain lengths of the oligomers and the free amino groups in the D-glucosamine units. In the current study, we report the synthesis of novel conjugate vaccine Tn-BSA-CTS with chitotriose as built-in adjuvant, along with an evaluation of the effect of adjuvant chitotriose (CTS). Immunological evaluations of the resultant conjugate vaccine revealed that Tn-BSA-CTS could provoke the highest titers of IgG antibodies (102,400). The Tn-BSA-CTS conjugate remarkably enhanced both humoral and cellular immunity. The obtained results demonstrate the potential of CTS as a novel vaccine adjuvant in the development of antitumor vaccine and the covalent linkage of tumor vaccine to CTS might be available strategy to increase the efficacy against cancer.

Automated summary

In this study, a novel conjugate vaccine Tn-BSA-CTS with chitotriose as built-in adjuvant was synthesized, and the effect of adjuvant chitotriose was evaluated. The immunological evaluations showed that Tn-BSA-CTS could stimulate the highest titers of IgG antibodies (102,400) and significantly enhance both humoral and cellular immunity. These results demonstrate the potential of CTS as a novel vaccine adjuvant and suggest that the covalent linkage of tumor vaccine to CTS could be an effective strategy to enhance the efficacy against cancer.